在现实世界中，从其他胰高血糖素样肽-1 受体激动剂转换为注射用司美格鲁肽可降低糖化血红蛋白（HbA1c）和体重。
Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.
机构信息
City Hospital, Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK.
School of Medicine, University of Nottingham, Nottingham, UK.
出版信息
Diabetes Obes Metab. 2022 Jul;24(7):1398-1401. doi: 10.1111/dom.14701. Epub 2022 Apr 7.
Abstract
The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure. The analysis, in this research letter, shows that decreases in HbA1c and weight associated with semaglutide occur irrespective of previous GLP-1RA use. However, HbA1c reductions were less if switched from dulaglutide or liraglutide and weight changes were attenuated if switched from dulaglutide or exenatide, potentially suggesting differing potencies between GLP-1RAs. Dedicated studies with head-to-head comparisons are needed to confirm these findings.
摘要
ABCD 司美格鲁肽审计旨在捕获在英国开始使用司美格鲁肽的人群的常规临床结果。之前的研究表明，HbA1c 和体重的降低与之前胰高血糖素样肽-1 受体激动剂（GLP-1RA）的暴露有关。在这篇研究快报的分析中，结果表明，与使用司美格鲁肽相关的 HbA1c 和体重的降低与之前是否使用 GLP-1RA 无关。然而，如果从度拉鲁肽或利拉鲁肽转换过来，HbA1c 的降低幅度较小，如果从度拉鲁肽或艾塞那肽转换过来，体重的变化则会减弱，这可能表明 GLP-1RAs 之间存在不同的效力。需要进行专门的头对头比较研究来证实这些发现。
相似文献
1
Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.
Diabetes Obes Metab. 2022 Jul;24(7):1398-1401. doi: 10.1111/dom.14701. Epub 2022 Apr 7.
2
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17.
3
Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.
Diabetes Obes Metab. 2019 Jan;21(1):43-51. doi: 10.1111/dom.13479. Epub 2018 Aug 23.
4
Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Clin Drug Investig. 2024 Apr;44(4):271-284. doi: 10.1007/s40261-024-01354-2. Epub 2024 Mar 20.
5
Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
J Med Econ. 2020 Jun;23(6):650-658. doi: 10.1080/13696998.2020.1722678. Epub 2020 Feb 7.
6
Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
Front Endocrinol (Lausanne). 2021 Jun 25;12:645617. doi: 10.3389/fendo.2021.645617. eCollection 2021.
7
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Adv Ther. 2020 Mar;37(3):1248-1259. doi: 10.1007/s12325-020-01242-z. Epub 2020 Feb 11.
8
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
Diabetes Obes Metab. 2016 Apr;18(4):317-32. doi: 10.1111/dom.12596. Epub 2015 Dec 29.
9
Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment.
Endocr Pract. 2024 Aug;30(8):701-709. doi: 10.1016/j.eprac.2024.05.005. Epub 2024 May 8.
10
Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
JAAPA. 2020 Aug;33(S8 Suppl 1):3-18. doi: 10.1097/01.JAA.0000669456.13763.bd.
引用本文的文献
1
Healthcare Resource Utilization and Costs in Individuals Who Discontinue Liraglutide and Who Switch from Liraglutide to Once-Weekly Injectable Semaglutide.
Diabetes Ther. 2025 May 16. doi: 10.1007/s13300-025-01741-8.
2
Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice.
Front Endocrinol (Lausanne). 2024 Jul 2;15:1394506. doi: 10.3389/fendo.2024.1394506. eCollection 2024.
3
Real-world HbA changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes.
J Diabetes Metab Disord. 2023 Nov 27;23(1):727-737. doi: 10.1007/s40200-023-01341-y. eCollection 2024 Jun.
4
Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study.
Diabetes Ther. 2024 Apr;15(4):843-853. doi: 10.1007/s13300-024-01547-0. Epub 2024 Feb 29.
5
Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study.
Diabetes Ther. 2024 Jan;15(1):111-126. doi: 10.1007/s13300-023-01493-3. Epub 2023 Oct 25.
本文引用的文献
1
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619.
2
Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.
Diabet Med. 2021 Oct;38(10):e14655. doi: 10.1111/dme.14655. Epub 2021 Aug 4.
3
Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.
Clin Ther. 2021 May;43(5):808-821. doi: 10.1016/j.clinthera.2021.03.003. Epub 2021 Mar 28.
4
Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study.
Diabetes Ther. 2021 Mar;12(3):943-954. doi: 10.1007/s13300-021-01016-y. Epub 2021 Feb 22.
5
Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study.
Diabetes Ther. 2021 Mar;12(3):879-896. doi: 10.1007/s13300-021-01010-4. Epub 2021 Feb 17.
6
Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study.
Diabetes Ther. 2021 Mar;12(3):801-811. doi: 10.1007/s13300-021-01015-z. Epub 2021 Feb 9.
7
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11).
Diabetes Care. 2021 Mar;44(3):765-773. doi: 10.2337/dc20-1473. Epub 2021 Jan 4.
8
A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.
Diabetes Ther. 2018 Jun;9(3):1149-1167. doi: 10.1007/s13300-018-0424-2. Epub 2018 Apr 19.
9
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Lancet Diabetes Endocrinol. 2018 Apr;6(4):275-286. doi: 10.1016/S2213-8587(18)30024-X. Epub 2018 Feb 1.
10
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Diabetes Care. 2018 Feb;41(2):258-266. doi: 10.2337/dc17-0417. Epub 2017 Dec 15.
Zotero 插件